Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055Gayle Marshall, Sylvie M. Guichard, Zoë Howard et al.|Biochemical Society Transactions|2011Cited by 38
157 The mTOR kinase inhibitor AZD8055 induces cell death in Her2+ tumours partially or intrinsically resistant to ErbB2 inhibitorsSarah V. Holt, Sylvie M. Guichard, Robert W. Wilkinson et al.|European Journal of Cancer Supplements|2010Cited by 1
Abstract 1654: Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancerSimon A. Woodcock, Caroline Phillips, Kevin J. Randall et al.|Cancer Research|2023Cited by 0